NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Kailera Therapeutics, Inc. (KLRA) Stock Analysis

Kailera Therapeutics, Inc. (KLRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KLRA

$12.92

+$0.03 (+0.23%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KLRA with… →

KLRA Key Statistics

As of Oct 21, 2026
Trading
Open
$12.91
Previous Close
$12.89
Day's Range
12.71–13.21
52-Week Range
9.76–28.23
Volume
1.28M
Valuation
Market Cap
$1.67B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.51
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$148.96M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
129.64M
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
978.84K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Kailera Therapeutics, Inc. (KLRA) has a market capitalization of $1.67B.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kailera Therapeutics, Inc. (KLRA) is capitalised at $1.67B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 145.

The most recent close on file for KLRA is $12.92, dated October 21, 2026. That is +$0.03 (+0.23%) against the previous close. The 52-week range on file runs from $9.76 to $28.23. The latest close sits 32.38% above that 52-week low.

Financial Health

In fiscal 2025, Kailera Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $148.96M. Earnings per share on a trailing basis come to −4.51.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The stored price history starts on April 17, 2026, and the total return since then is −50.31%.

Growth & Income

The record shows no dividend for KLRA.

So far in 2026 the total return is −50.31%.

Peer Comparison

Kailera Therapeutics, Inc. (KLRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kailera Therapeutics, Inc. KLRA $1.67B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Kailera Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Visit website →